Melanotan II
These sentences are taken from FDA’s compounding-risk page and, where noted, the July 2026 advisory-committee agenda. They are not a finding that a substance works.
What the opened sources say
Section titled “What the opened sources say”- Melanotan II is on the withdrawn-nomination list. FDA says compounded drugs containing it may pose an immunogenicity risk for certain routes because of aggregation or peptide-related impurities.
- FDA says published case reports discuss serious adverse events including melanoma, posterior reversible encephalopathy syndrome, sympathomimetic toxidrome, and priapism. This page does not re-read those case reports and does not give frequencies.
Not stated here
Section titled “Not stated here”Legal effect beyond the words on those pages is not interpreted. No animal or human study is summarized, because none was opened.
This page does not give doses, titration schedules, injection or implantation technique, preparation steps, or places to purchase a product.
See also
Section titled “See also”Page record
Sources
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (primary, accessed 2026-11-20)
- July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee (primary, accessed 2026-11-20)
Referenced by
- BPC-157
- Bremelanotide
- CJC-1295
- FDA Category 2 and withdrawn nominations
- GHK-Cu
- Ipamorelin
- MOTS-c
- PCAC meeting, 23–24 July 2026
- Peptides
- TB-500
A link from another wiki page is not evidence. Facts should point at the sources above.